摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(氮杂啶-1-基羰基)-5-溴嘧啶 | 915948-90-2

中文名称
2-(氮杂啶-1-基羰基)-5-溴嘧啶
中文别名
——
英文名称
2-(azetidin-1-ylcarbonyl)-5-bromopyrimidine
英文别名
azetidin-1-yl(5-bromopyrimidin-2-yl)methanone;azetidin-1-yl-(5-bromopyrimidin-2-yl)methanone
2-(氮杂啶-1-基羰基)-5-溴嘧啶化学式
CAS
915948-90-2
化学式
C8H8BrN3O
mdl
——
分子量
242.075
InChiKey
IJGOGKNBAGFIME-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    46.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS
    申请人:Bai Hao
    公开号:US20080280875A1
    公开(公告)日:2008-11-13
    The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R 1 , R 1a , R 2 , R 3 , R 4 , L 2 , n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    本发明涉及以下式(I)的化合物:或其药用可接受的盐或溶剂,其中:环A为(4-12)成员杂环基;环B是从以下组中选择的融合苯环之一:环A、环B、环C、R1、R1a、R2、R3、R4、L2、n、t、w和z如规范中所定义。本发明还涉及包括式(I)的化合物的药物组合物以及治疗通过调节葡萄糖激酶介导的疾病的方法,该方法包括向哺乳动物施用有效量的式(I)的化合物。
  • HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES
    申请人:MCKERRECHER Darren
    公开号:US20090029905A1
    公开(公告)日:2009-01-29
    Compounds of formula (I) wherein R 1 , HET-1 and HET-2 are as described in the specification, and their salts and prodrugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
    式(I)中,R1、HET-1和HET-2的化合物,以及它们的盐和前药,是葡萄糖激酶(GLK)的激活剂,因此在治疗例如2型糖尿病方面非常有用。本文还描述了制备式(I)化合物的过程。
  • HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS
    申请人:Caulkett Peter William Rodney
    公开号:US20090105263A1
    公开(公告)日:2009-04-23
    Compounds of Formula (I): wherein R 1 to R 11 , A and X 1 to X 3 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of Formula (I) are also described.
    公式(I)的化合物:其中R1到R11,A和X1到X3如说明书中所述,并且它们的盐,是葡萄糖激酶(GLK)的激活剂,因此在治疗例如二型糖尿病方面是有用的。还描述了制备公式(I)化合物的过程。
  • Fused phenyl amido heterocyclic compounds
    申请人:Pfizer Inc
    公开号:US07842713B2
    公开(公告)日:2010-11-30
    The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    本发明涉及式(I)的化合物:或其药学上可接受的盐或溶剂,其中:环A是(4-12)成员的杂环;环B是选自以下组的融合苯环:环A,环B,环C,R1,R1a,R2,R3,R4,L2,n,t,w和z在规范中定义。本发明还涉及包括式(I)的化合物的制药组合物和治疗通过调节葡萄糖激酶介导的疾病的方法,该方法包括向哺乳动物施用式(I)的化合物的有效量。
  • 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS
    申请人:Caulkett Peter William Rodney
    公开号:US20110059941A1
    公开(公告)日:2011-03-10
    Compounds of Formula (I), wherein R 1 -R 10 , A and X 1 to X 3 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
    公式(I)的化合物,其中R1-R10,A和X1到X3如规范所述,并且它们的盐和前药是葡萄糖激酶(GLK)的激活剂,因此在治疗例如2型糖尿病方面是有用的。还描述了制备公式(I)化合物的过程。
查看更多